Evidence map›Paper›PMID 38230434›Full record

ReviewThe Journal of pathology2024

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.

Chowdhury Arif Jahangir, David B Page, Glenn Broeckx, Claudia A Gonzalez, Caoimbhe Burke, Clodagh Murphy, Jorge S Reis-Filho, Amy Ly, Paul W Harms, Rajarsi R Gupta and 127 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Review
  11. New Insights into Personalized Surgical Oncology.Journal of personalized medicine · 2025
    Article
  12. Closer proximity of pre-treatment CD4Translational lung cancer research · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

137 authors at 20 institutions in 32 countries.

Chowdhury Arif JahangirUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.ORCID 0000-0002-5389-7275
David B PageEarle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.ORCID 0000-0001-9264-4628
Glenn BroeckxDepartment of Pathology PA2, GZA-ZNA Hospitals, Antwerp, Belgium.
Claudia A GonzalezUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Caoimbhe BurkeUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Clodagh MurphyUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Jorge S Reis-FilhoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2969-3173
Amy LyDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Paul W HarmsDepartments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI, USA.
Rajarsi R GuptaDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA.ORCID 0000-0002-1577-8718
Michael ViethInstitute of Pathology, Klinikum Bayreuth GmbH, Friedrich-Alexander-University Erlangen-Nuremberg, Bayreuth, Germany.
Akira I HidaDepartment of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan.
Mohamed KahilaDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Zuzana KosDepartment of Pathology and Laboratory Medicine, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada.
Paul J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Sara VerbandtDigestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Jeppe ThagaardTechnical University of Denmark, Kgs. Lyngby, Denmark.
Reena KhiroyaDepartment of Cellular Pathology, University College Hospital, London, UK.
Khalid AbduljabbarCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Gabriela Acosta HaabHospital Maria Curie, Buenos Aires, Argentina.
Balazs AcsDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Sylvia AdamsPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Jonas S AlmeidaDivision of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Rockville, MD, USA.
Isabel Alvarado-CabreroOncology Hospital, Star Medica Centro, Juarez City, Mexico.
Farid Azmoudeh-ArdalanTehran University of Medical Sciences, Tehran, Iran.
Sunil BadveDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Winship Cancer Institute, Atlanta, GA, USA.
Nurkhairul Bariyah BaharunThe National University of Malaysia, Kuala Lumpur, Malaysia.
Enrique R BellolioDepartamento de Anatomía Patológica, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile.
Vydehi BheemarajuDepartment of Pathology, Narayana Medical College, Nellore, India.
Kim Rm BlenmanDepartment of Internal Medicine Section of Medical Oncology and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Luciana Botinelly Mendonça FujimotoAmazonas Federal University, Manaus, Brazil.
Octavio BurguesPathology Department, Hospital Cliníco Universitario de Valencia/Incliva, Valencia, Spain.
Alexandros ChardasDepartment of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK.ORCID 0000-0001-9906-7552
Maggie Chon U CheangHead of Integrative Genomics Analysis in Clinical Trials, ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
Francesco CiompiDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Lee Ad CooperDepartment of Pathology, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
An CoosemansDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Leuven, Belgium.
Germán CorredorBiomedical Engineering Department, Emory University, Atlanta, GA, USA.
Flavio Luis Dantas PortelaHospital Universitário Getúlio Vargas, Manaus, Brazil.ORCID 0000-0003-0188-3709
Frederik DemanDepartment of Pathology PA2, GZA-ZNA Hospitals, Antwerp, Belgium.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Sarah N DudgeonComputational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
Mahmoud ElghazawyUniversity of Surrey, Guildford, UK.ORCID 0000-0002-3100-7606
Claudio Fernandez-MartínInstituto Universitario de Investigación en Tecnología Centrada en el Ser Humano, HUMAN-tech, Universitat Politècnica de València, Valencia, Spain.
Susan FinebergMontefiore Medical Center and the Albert Einstein College of Medicine, New York, NY, USA.
Stephen B FoxPathology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Jennifer M GiltnaneGenentech, San Francisco, CA, USA.
Sacha GnjaticDepartment of Oncological Sciences, Medicine Hem/Onc, and Pathology, Tisch Cancer Institute - Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Paula I Gonzalez-EricssonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-6292-6963
Anita GrigoriadisCancer Bioinformatics, Faculty of Life Sciences and Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.ORCID 0000-0003-3434-201X
Niels HalamaDepartment of Translational Immunotherapy, German Cancer Research Center, Heidelberg, Germany.
Matthew G HannaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Aparna HarbhajankaCase Western University, Cleveland, OH, USA.
Steven N HartDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7714-2734
Johan HartmanDepartment of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-6500-8527
Stephen HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hugo M HorlingsDivision of Pathology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
Zaheed HusainPraava Health, Dhaka, Bangladesh.
Sheeba IrshadKing's College London & Guys & St Thomas NHS Trust, London, UK.
Emiel Am JanssenDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
Tatsuki R KataokaDepartment of Pathology, Iwate Medical University, Morioka, Japan.ORCID 0000-0003-3095-8976
Kosuke KawaguchiDepartment of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Andrey I KhramtsovDepartment of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Umay KirazDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
Pawan KirtaniHistopathology, Aakash Healthcare Super Speciality Hospital, New Delhi, India.
Liudmila L KodachDepartment of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Konstanty KorskiData, Analytics and Imaging, Product Development, F. Hoffmann-La Roche AG, Basel, Switzerland.
Guray AkturkTranslational Molecular Biomarkers, Merck & Co., Inc., Kenilworth, NJ, USA.
Ely ScottTranslational Medicine, Bristol Myers Squibb, Princeton, NJ, USA.
Anikó KovácsDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Anne-Vibeke LaenkholmDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
Corinna Lang-SchwarzInstitute of Pathology, Klinikum Bayreuth GmbH, Friedrich-Alexander-University Erlangen-Nuremberg, Bayreuth, Germany.
Denis LarsimontInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Jochen K LennerzCenter for Integrated Diagnostics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Marvin LerousseauCentre for Computational Biology (CBIO), Mines Paris, PSL University, Paris, France.
Xiaoxian LiDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Radiology and Imaging Sciences, Biomedical Informatics, Pathology, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Sai K MaleyNRG Oncology/NSABP Foundation, Pittsburgh, PA, USA.
Vidya Manur NarasimhamurthyManipal Hospitals, Bangalore, India.
Douglas K MarksPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Elizabeth S McDonaldBreast Cancer Translational Research Group, University of Pennsylvania, Philadelphia, PA, USA.
Ravi MehrotraIndian Cancer Genomic Atlas, Pune, India.
Stefan MichielsOffice of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, Ligue Contre le Cancer labeled Team, Villejuif, France.
Durga KharidehalDepartment of Pathology, Narayana Medical College and Hospital, Nellore, India.
Fayyaz Ul Amir Afsar MinhasTissue Image Analytics Centre, Warwick Cancer Research Centre, PathLAKE Consortium, Department of Computer Science, University of Warwick, Coventry, UK.
Shachi MittalDepartment of Chemical Engineering, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
David A MooreCRUK Lung Cancer Centre of Excellence, UCL and Cellular Pathology Department, UCLH, London, UK.
Shamim MushtaqDepartment of Biochemistry, Ziauddin University, Karachi, Pakistan.
Hussain NighatPathology and Laboratory Medicine, All India Institute of Medical Sciences, Raipur, India.
Thomas PapathomasInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Frederique Penault-LlorcaService de Pathologie et Biopathologie, Centre Jean PERRIN, INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Rashindrie D PereraSchool of Electrical, Mechanical and Infrastructure Engineering, University of Melbourne, Melbourne, Victoria, Australia.
Christopher J PinardRadiogenomics Laboratory, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Juan Carlos Pinto-CardenasDiagnostico de Salud Animal SA, Ciudad de México, Mexico.
Giancarlo PruneriDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Lajos PusztaiYale Cancer Center, Yale University, New Haven, CT, USA.
Nasir Mahmood RajpootUniversity of Warwick, Coventry, UK.
Bernardo Leon RapoportThe Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
Tilman T RauInstitute of Pathology, University Hospital Düsseldorf and Heinrich-Heine-University, Düsseldorf, Germany.ORCID 0000-0002-1251-950X
Joana M RibeiroBreast Unit, Institute Gustave Roussy, Villejuif, France.
David RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5820-4397
Anne Vincent-SalomonDepartment of Diagnostic and Theranostic Medicine, Institut Curie, University Paris-Sciences et Lettres, Paris, France.
Joel SaltzDepartment of Biomedical Informatics, Stony Brook Medicine, New York, NY, USA.
Shahin SayedDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Evangelos HytopoulosDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Sarah MahonMater Misericordiae University Hospital, Dublin, Ireland.
Kalliopi P SiziopikouDepartment of Pathology, Section of Breast Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Christos SotiriouBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Centers for Personalized Medicine (ZPM), Heidelberg, Germany.
Maher A SughayerKing Hussein Cancer Center, Amman, Jordan.
Daniel SurDepartment of Medical Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
Fraser SymmansUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sunao TanakaKyoto University, Kyoto, Japan.
Timothy TaxterTempus Labs, Chicago, IL, USA.
Sabine TejparDigestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Jonas TeuwenAI for Oncology Lab, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
E Aubrey ThompsonMayo Clinic, Jacksonville, FL, USA.
Trine TrammDepartment of Pathology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
William T TranDepartment of Radiation Oncology, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada.
Jeroen van der LaakHead of Integrative Genomics Analysis in Clinical Trials, ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
Gregory E VergheseCancer Bioinformatics, Faculty of Life Sciences and Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.ORCID 0009-0006-7638-6431
Giuseppe VialeDepartment of Pathology, European Institute of Oncology & University of Milan, Milan, Italy.
Noorul WahabTissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK.ORCID 0000-0002-1251-1559
Thomas WalterCentre for Computational Biology (CBIO), Mines Paris, PSL University, Paris, France.
Yannick WaumansCellCarta NV, Antwerp, Belgium.
Hannah Y WenMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Wentao YangFudan Medical University Shanghai Cancer Center, Shanghai, PR China.
Yinyin YuanDepartment of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John BartlettUniversity of Edinburgh, Edinburgh, UK.
Sibylle LoiblDepartment of Medicine and Research, German Breast Group, Neu-Isenburg, Germany.
Carsten DenkertInstitut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg, Marburg, Germany.
Peter SavasDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sherene LoiDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Elisabeth Specht StovgaardDepartment of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Roberto SalgadoDepartment of Pathology PA2, GZA-ZNA Hospitals, Antwerp, Belgium.
William M GallagherUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Arman RahmanUCD School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland.
University College Dublin · IEInserm · FRThe University of Melbourne · AUEmory University · USInstitute of Cancer Research · GBKing's College London · GBMemorial Sloan Kettering Cancer Center · USThe Netherlands Cancer Institute · NLUniversity of Warwick · GBYale University · USAga Khan University Nairobi · KEBayreuth Medical Center · DEKarolinska University Hospital · SEKU Leuven · BEKyoto University · JPNarayana Dental College and Hospital · INNorthwestern University · USNYU Langone Health · USStavanger University Hospital · NOSunnybrook Health Science Centre · CA

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5M
Experimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3M
TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision MedicineU24CA215109 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BANERJEE, IMON, PRIOR, FRED WILLIAM · 2017 to 2021
$8.5M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0M
BLRD VA I01 BX004121Cancer Research UK C45982/A21808Cancer Research UK CRUK/07/012Cancer Research UK KCL-BCN-Q3NCI NIH HHS 1U01CA239055-01NCI NIH HHS 1U01CA248226-01NCI NIH HHS 1U54CA254566-01NCI NIH HHS P30 CA196521NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA202752NCI NIH HHS R01CA202752-01A1NCI NIH HHS R01 CA208236NCI NIH HHS R01CA208236-01A1NCI NIH HHS R01 CA216579NCI NIH HHS R01CA216579-01A1NCI NIH HHS R01 CA220581NCI NIH HHS R01CA220581-01A1NCI NIH HHS R01 CA249992NCI NIH HHS R01CA249992-01A1NCI NIH HHS R01 CA257612NCI NIH HHS R01CA257612-01A1NCI NIH HHS R01CA26820701A1NCI NIH HHS R01 CA268287NCI NIH HHS R01CA268287A1NCI NIH HHS R33 CA263705NCI NIH HHS R37 CA225655NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U01CA269181NCI NIH HHS U24 CA215109NCI NIH HHS U24 CA224319NCI NIH HHS U54 CA254566NCI NIH HHS UH3 CA225021NIBIB NIH HHS 1R43EB028736-01NIBIB NIH HHS R43 EB028736NIDDK NIH HHS U01 DK124165NIH HHS CA196521NIH HHS CA224319NIH HHS CA263705NIH HHS DK124165NIH HHS R37 CA225655
6 · The paper itself

Abstract

Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high-throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi-marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Breast NeoplasmsBiomarkers, TumorFemaleHumansPhenotypePrognosisTumor MicroenvironmentUnited KingdomBiomarkers, Tumorcancer prognosisclinical integrationdigital image analysismultiplex imagingmultiplex immunofluorescencemultiplex immunohistochemistrytherapy responsetumour immune profilingtumour infiltrating lymphocytes

Identifiers

PMID38230434
PMCPMC11288342
OpenAlexW4390950175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.